Table 1.
Reported Incidence of Cancer Diagnoses (or Cancer Deaths)
| Trial | No. | Duration (Years) | Placebo | Omega-3 |
|---|---|---|---|---|
| AlphaOmega (prostate cancer) | 4,837 | 3.4 | 0.8% | 1.4% |
| GISSI–Heart Failure (cancer death) | 6,975 | 3.9 | 3.2% | 3.1% |
| GISSI–Prevenzione | 11,320 | 3.5 | 2.25% | 2.65% |
| JELIS | 18,645 | 4.6 | 2.4% | 2.60% |
| SU.FOL.OM3 (cancer death) | 2,501 | 4.2 | 6.5% | 7.0% |
| ORIGIN | 12,536 | 6.2 | No difference in rate of cancer | No difference in rate of cancer |
| Risk and Prevention | 12,513 | 5.0 | 7.2% | 7.9% |
| OMEGA | 3,851 | 1.0 | 1.4% | 1.7% |
GISSI = Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico; JELIS = Japan eicosapentaenoic acid (EPA) Lipid Intervention Study; ORIGIN = Outcome Reduction with Initial Glargine Intervention; SU.FOL.OM3 = SUpplementation with FOlate, vitamin B6 and B12 and/or OMega-3 fatty acids.